Menopause
Conference Coverage
Biomarkers predict VTE risk with menopausal oral hormone therapy
CHICAGO – Pretreatment high D-dimer spells 500% increased VTE risk on oral hormone therapy.
Latest News
Soy didn’t up all-cause mortality in breast cancer survivors
The ongoing study tracks with previous work showing no risk from dietary soy.
Expert Commentary
Is vaginal estrogen used for GSM associated with a higher risk of CVD or cancer?
No. Vaginal estrogen use (average duration of use, 37.5 months) for genitourinary symptoms of menopause (GSM)...
Expert Commentary
Does the type of menopausal HT used increase the risk of venous thromboembolism?
Yes, according to a case-control study that analyzed data from 2 large UK databases in which 80,396 women aged...
From the Journals
Most oral HRT linked to increased VTE risk
Sponsored Supplement
Ospemifene, an oral SERM for dyspareunia of menopause: Is it being underutilized?
Expert Commentary
How does HT in recent and 10+ years past menopause affect atherosclerosis progression?
Secondary analysis of ELITE trial data among 596 women in early (<6 years) and late (≥10 years) postmenopause...
From the Journals
Healthier lifestyle in midlife women reduces subclinical carotid atherosclerosis
Menopausal women who choose a healthier lifestyle – particularly not smoking – have less subclinical carotid atherosclerosis.
Clinical Review
Managing menopausal vasomotor and genitourinary symptoms after breast cancer
Two cases on selecting safe and useful treatments for survivors of breast cancer experiencing distressing quality-of-life...
From the Journals
Intimate partner violence and PTSD increase menopausal symptom risk
Women who have PTSD related to experiencing intimate partner violence and sexual assault are more likely to experience menopausal symptoms.
Commentary
To prevent fractures, treating only women with osteoporosis is not enough
In older osteopenic women, intravenous zoledronic acid effectively prevents fragility fractures.
Conference Coverage
Estetrol safely limited menopause symptoms in a phase 2b study
E4 has “a remarkably safe profile,” which Dr. Wulf H. Utian describes as “the first natural oral estrogen with the safety profile of a transdermal...